Scientific Reports
April 7, 2022
Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al.
56 citations
People who have used psilocybin at some point in their lives have 30% lower odds of having opioid use disorder, based on data from a large U.S. national survey. No other classic psychedelic substances—such as LSD, peyote, or mescaline—showed a similar association. Psilocybin use was also linked to lower odds of meeting seven of the 11 diagnostic criteria for opioid use disorder. These findings suggest psilocybin may hold promise as a treatment, but clinical trials are needed to establish causality.
Scientific reports
October 10, 2022
Grant M. Jones, Matthew K. Nock
46 citations
Lifetime use of MDMA or psilocybin is associated with lower odds of psychological distress and suicidality among White individuals, but these protective associations are far fewer for racial and ethnic minorities. Analyzing data from over 484,000 participants in the National Survey on Drug Use and Health (2008–2019), race and ethnicity significantly moderated the links between psychedelic use and mental health outcomes. The findings highlight the need for further research on how identity factors such as race, ethnicity, socioeconomic status, and sexual/gender minority status influence the effects of psychedelic substances.
Scientific Reports
February 16, 2022
Grant M. Jones, Matthew K. Nock
44 citations
Lifetime use of peyote, but not other classic psychedelics, is associated with more than 50% lower odds of cocaine use disorder (CUD) in a nationally representative U.S. sample of 214,505 adults from the 2015–2019 National Survey on Drug Use and Health. Peyote also reduced odds for seven of 11 specific CUD criteria, with adjusted odds ratios ranging from 0.26 to 0.47. Other psychedelics (mescaline, psilocybin, LSD) showed either no association or increased odds of CUD. The authors suggest that third variables such as demographic or personality profiles of peyote users may explain the association, and call for longitudinal studies to test temporal links.
Scientific Reports
June 22, 2022
Grant Jones, Joshua Lipson, Matthew K. Nock
31 citations
Lifetime use of psilocybin, peyote, or mescaline is associated with lower odds of current nicotine dependence, while lifetime LSD use is linked to higher odds. Analyzing 214,505 participants from the 2015–2019 National Survey on Drug Use and Health, multivariable logistic regression showed psilocybin use corresponded to reduced odds of nicotine dependence (adjusted odds ratio 0.87–0.93). Peyote and mescaline use also reduced odds on multiple subdomains of the Nicotine Dependence Syndrome Scale (adjusted odds ratio 0.79–0.91). LSD use was associated with increased odds (adjusted odds ratio 1.17–1.24). These observational findings suggest potential for tryptamine and phenethylamine psychedelics in smoking cessation research, but causal relationships require experimental testing.
Frontiers in Psychiatry
August 24, 2023
Grant Jones, Patrick Mair, Maha Al‐suwaidi et al.
10 citations
Lifetime psilocybin use is associated with lower odds of arrest for property crime, assault, serious violence, and miscellaneous crimes in a large US sample. However, race and ethnicity moderate these associations: psilocybin conferred reduced odds of at least one crime arrest outcome for White, Indigenous, Asian, and Multiracial participants, but not for Black or Hispanic participants. The authors suggest that structural factors such as systemic racism may underlie these differences and call for intersectional research on sociodemographic factors, psychedelic use, and crime.
Frontiers in Psychiatry
June 24, 2024
Grant M. Jones, Jocelyn A. Ricard, Matthew K. Nock
5 citations
Hypertension disproportionately affects racial and ethnic minorities. Using National Survey on Drug Use and Health data (2005–2014), the authors examined whether race and ethnicity modify the association between psilocybin use and past-year hypertension. Hispanic identity moderated this association. Non-Hispanic White individuals who used psilocybin had 17% lower odds of hypertension (adjusted odds ratio: 0.83), but no such protective association appeared for other racial or ethnic groups. The results indicate that the relationship between psychedelics and hypertension may differ by race and ethnicity, warranting further longitudinal and clinical research.